Viome Life Sciences

Executive Summary

Viome Life Sciences is a private biotechnology company leveraging metatranscriptomics and machine learning to decode the interplay between human and microbial gene expression. Founded in 2016 and based in Bellevue, Washington, the company operates across three verticals: prevention, diagnostics, and therapeutics. By analyzing RNA from the microbiome, Viome aims to predict and prevent chronic diseases before they manifest. The company has raised significant venture funding and launched direct-to-consumer gut microbiome testing, while also advancing therapeutic candidates in oncology and metabolic disorders. Viome's systems biology approach differentiates it from competitors focused solely on DNA sequencing, offering real-time insights into gene activity. However, as a private company with limited public clinical data, its valuation and revenue remain undisclosed. The path to commercialization involves scaling its diagnostic platform and progressing therapeutic programs through clinical trials. With a strong scientific foundation and growing consumer adoption, Viome is positioned to disrupt the preventive health market, though execution risks persist.

Upcoming Catalysts (preview)

• Q4 2026Commercial launch of new therapeutic candidate for metabolic disease30% success
• Q2 2026Publication of clinical validation data for cancer detection test60% success
• Q3 2026Series D funding round or strategic partnership announcement50% success